• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

105.78 +3.00 (+2.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
February 13, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
February 05, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
January 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals ↗
December 20, 2024
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts ↗
November 25, 2024
 
Via Benzinga
News headline image
What's Next: Rhythm Pharmaceuticals's Earnings Preview ↗
November 04, 2024
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential ↗
December 20, 2024
Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
December 20, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to
December 03, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know ↗
October 25, 2024
 
Via Benzinga
News headline image
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals ↗
October 07, 2024
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
November 18, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
November 13, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 13, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals ↗
September 18, 2024
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts ↗
July 25, 2024
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
November 06, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
November 05, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
November 04, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
October 24, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
October 23, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
October 08, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
September 16, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
August 26, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
August 26, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
August 13, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 ↗
August 06, 2024
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
August 06, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
July 31, 2024
IMCIVREE now authorized as treatment of obesity and control of hunger in adult patients and pediatric patients 2 years old or older with Bardet Biedl syndrome or POMC, PCSK1, or LEPR deficiency 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 23, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap